Anti-tumor activity of olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in cultured endometrial carcinoma cells

Olaparib: a promising PARP inhibitor in ovarian cancer therapy

(2013) Ying Chen et al.   ARCHIVES OF GYNECOLOGY AND OBSTETRICS

RAD51C-Deficient Cancer Cells Are Highly Sensitive to the PARP Inhibitor Olaparib

(2013) A. Min et al.   MOLECULAR CANCER THERAPEUTICS

PARP Inhibition Sensitizes to Low Dose-Rate Radiation TMPRSS2-ERG Fusion Gene-Expressing and PTEN-Deficient Prostate Cancer Cells

(2013) Payel Chatterjee et al.   PLoS One

Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells

(2012) Hsiao-Ching Chuang et al.   BREAST CANCER RESEARCH AND TREATMENT

Cancer statistics, 2012

(2012) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Genome-Wide Single Nucleotide Polymorphism Arrays as a Diagnostic Tool in Patients With Synchronous Endometrial and Ovarian Cancer

(2012) Yuji Ikeda et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

Synergistic Effect of Olaparib with Combination of Cisplatin on PTEN-Deficient Lung Cancer Cells

(2012) D. Minami et al.   MOLECULAR CANCER RESEARCH

Genotype-Dependent Efficacy of a Dual PI3K/mTOR Inhibitor, NVP-BEZ235, and an mTOR Inhibitor, RAD001, in Endometrial Carcinomas

(2012) Keiko Shoji et al.   PLoS One

Multifunctional transcription factor TFII-I is an activator of BRCA1 function

(2011) M Tanikawa et al.   BRITISH JOURNAL OF CANCER

Synthetic lethality of PARP inhibition in cancers lackingBRCA1andBRCA2mutations

(2011) Konstantin J. Dedes et al.   CELL CYCLE

PTEN Deletion in Prostate Cancer Cells Does Not Associate with Loss of RAD51 Function: Implications for Radiotherapy and Chemotherapy

(2011) M. Fraser et al.   CLINICAL CANCER RESEARCH

Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer

(2011) Martin D. Forster et al.   Nature Reviews Clinical Oncology

PARP Inhibitors in BRCA Gene-Mutated Ovarian Cancer and Beyond

(2011) Susana Banerjee et al.   Current Oncology Reports

PTEN Loss Compromises Homologous Recombination Repair in Astrocytes: Implications for Glioblastoma Therapy with Temozolomide or Poly(ADP-Ribose) Polymerase Inhibitors

(2010) B. McEllin et al.   CANCER RESEARCH

ATM Deficiency Sensitizes Mantle Cell Lymphoma Cells to Poly(ADP-Ribose) Polymerase-1 Inhibitors

(2010) C. T. Williamson et al.   MOLECULAR CANCER THERAPEUTICS

PTEN Deficiency in Endometrioid Endometrial Adenocarcinomas Predicts Sensitivity to PARP Inhibitors

(2010) K. J. Dedes et al.   Science Translational Medicine

The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas

(2009) K Shoji et al.   BRITISH JOURNAL OF CANCER

PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination

(2009) Helen E Bryant et al.   EMBO JOURNAL

Synthetic lethal targeting ofPTENmutant cells with PARP inhibitors

(2009) Ana M. Mendes-Pereira et al.   EMBO Molecular Medicine

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers

(2009) Peter C. Fong et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mechanism of Eukaryotic Homologous Recombination

(2008) Joseph San Filippo et al.   Annual Review of Biochemistry

PIK3CA Cooperates with Other Phosphatidylinositol 3'-Kinase Pathway Mutations to Effect Oncogenic Transformation

(2008) K. Oda et al.   CANCER RESEARCH

4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: A Novel Bioavailable Inhibitor of Poly(ADP-ribose) Polymerase-1

(2008) Keith A. Menear et al.   JOURNAL OF MEDICINAL CHEMISTRY